Abstract
Diabetes is one of the principal problems concerning the health of contemporary society. It causes numerous dangerous complications among which cardiological complications take up the fi rst place because they can lead to quick deaths of patients. Cardiomyopathy is an essential and at the same time insidiously developing complication of diabetes. It is the result of the combined action of unfavourable factors such as: endotheliopathy, autonomic system dysfunction, disturbances of carbohydrate metabolism and consequently ischaemic heart disease as well as arterial hypertension. The problem of diabetic cardiomyopathy demands a regular monitoring of cardiovascular system and a quick introduction of pharmacological treatment at its fi rst symptoms. There are opinions more and more frequently presented that suggest prophylactic administration of cardiological drugs in the group of asymptomatic patients. According to the European Society of Cardiology, two groups of medications are recommended: angiotensin converting enzyme inhibitors and beta-adrenalytics. The treatment of cardiomyopathy in diabetic patients should also include normalization of the body mass and an accurate metabolic compensation.
References
1. Avogaro A., Vigilide Kreutzenberg S., Negut C. et al.: Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol. 93 (8A): 13A–16A, April 2004. doi:10.1016/j.amjcard.2003.11.003. PMID 15094099.
2. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Study Evaluation Study Investigators. Lancet, 355, 253, 2000.
3. Hunt S. A., Baker D. W., Chin M. H. et al.: American College of Cardiology/ American Heart Association. ACC/AHA Guidelines for the evaluation and Management of Heart Failure in Adult: Executive Summary. A Report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the evaluation and Management of Heart Failure). J. Am. Coll Cardiol., 38, 2101, 2001.
4. Kannel W. B., Mc Gee D. L.: Diabetes and cardiovascular disease. The Framingham study. JAMA 241, (19): 2035–8, May 1979. doi:10.1001/jama.241.19.2035. PMID 430798.
5. Moir S., Hanekom L., Fang Z. Y. et al.: Relationship between myocardial perfusion and dysfunction in diabetic cardiomyopathy: a study of quantitative contrast echocardiography and strain rate imaging. Heart, 92, October 2006.
6. Niebisz A. B., Karnafel W.: Przewlekła niewydolność serca w cukrzycy, Kardiologia na co Dzień, 2 (1), 31, 2007.
7. Ryden L., Stand l E., Bartnik M. et al.: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28, 88, 2007.
8. Shekel l e P. G., Rich M. W., Morton S. C. et al.: Efficacy of angiotensin-converting enzyme inhibitor and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J. Am. Coll Cardiol., 41, 1529, 2003.
9. Shindler D. M., Kostis J. B., Yusuf S. et al.: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVED) Trials and Registry. Am. J. Cardiol., 77, 1017, 1996.
10. Tatoń J., Czech A., Bernas M.: Diabetologia kliniczna, PZWL, 54, Warszawa 2008.
11. Zuanetti G., Latini R., Maggioni A. P. et al.: Effect of ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation, 96, 4239, 1997.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2009 Authors